PDSB - PDS Biotechnology Corp logo

PDSB

PDS Biotechnology Corp

Rev โ€”top 1%10Y
Hold

PDS Biotechnology Corp develops targeted cancer immunotherapies, including Versamune HPV for various cancers. Its pipeline features PDS0102 for acute myeloid leukemia and PDS0202, an investigational influenza vaccine, among others.

โš•๏ธ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago โ†’$1today

Score Overview

1 Year
Scoreโ€”
Net Growth3.30%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-97.15%
Net Trend60%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth14.08%
Net Trend50%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency
All Time
Scoreโ€”
Net Growth-18.79%
Net Trend45%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

PDS Biotechnology Corp fundamental performance

Across PDS Biotechnology Corp's full reported history, from 2015 to 2025, net income went from -$ 28M to -$ 34M. Revenue increased in 0% of the years measured; net income in 45%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.24โ€”
1 Year2025-08-12
$ 1.23-80.33%
5 Years2021-08-12
$ 10.89-97.78%
10 Years2016-08-12
$ 194.80-99.88%
All Time2015-10-01
$ 258.80-99.91%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 33M$ 21M
2025$ 0.00-$ 34M$ 26M
2024$ 0.00-$ 37M$ 41M
2023$ 0.00-$ 42M$ 56M
2022$ 0.00-$ 40M$ 73M
2021$ 0.00-$ 16M$ 65M
2020$ 0.00-$ 14M$ 28M
2019$ 0.00-$ 6M$ 12M
2018$ 0.00-$ 40M$ 34M
2017$ 0.00-$ 50M$ 88M
2016$ 0.00-$ 38M$ 106M
IPO2015-$ 28M$ 130M

Explore beyond PDSB

You're looking at PDS Biotechnology Corp. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies